热门资讯> 正文
Aptose Biosciences GAAP每股收益为-36.38美元
2025-03-28 20:17
- Aptose Biosciences press release (NASDAQ:APTO): FY GAAP EPS of -$36.38.
- Total cash, cash equivalents and restricted cash equivalents as of December 31, 2024, were $6.7 million. Based on current operations, the Company expects that cash on hand and available capital provides the Company with sufficient resources to fund planned Company operations including research and development until April 2025.
More on Aptose Biosciences
- Aptose Biosciences approves 1-for-30 reverse share split to restore Nasdaq compliance
- Aptose Biosciences announces resale of 12.03M shares by Keystone Capital Partners
- Seeking Alpha’s Quant Rating on Aptose Biosciences
- Historical earnings data for Aptose Biosciences
- Financial information for Aptose Biosciences
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
